BTIG Research reiterated their buy rating on shares of Cerus Co. (NASDAQ:CERS) in a research report released on Sunday. The brokerage currently has a $5.00 price objective on the biotechnology company’s stock.
A number of other analysts have also recently issued reports on the stock. Cowen and Company cut their target price on shares of Cerus from $9.50 to $7.00 and set an outperform rating for the company in a research note on Monday, April 17th. Cantor Fitzgerald set a $9.00 target price on shares of Cerus and gave the stock a buy rating in a research note on Thursday, May 4th. Zacks Investment Research upgraded shares of Cerus from a sell rating to a hold rating in a research note on Wednesday, March 8th. Finally, FBR & Co set a $10.00 target price on shares of Cerus and gave the stock a buy rating in a research note on Wednesday, March 8th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Cerus presently has a consensus rating of Buy and a consensus price target of $7.80.
Cerus (NASDAQ:CERS) opened at 2.35 on Friday. The stock’s 50 day moving average is $3.62 and its 200-day moving average is $4.32. Cerus has a 12 month low of $1.93 and a 12 month high of $7.64. The firm’s market cap is $244.25 million.
Cerus (NASDAQ:CERS) last posted its earnings results on Thursday, May 4th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by $0.02. The company had revenue of $7.01 million for the quarter, compared to analyst estimates of $8.98 million. Cerus had a negative return on equity of 76.76% and a negative net margin of 174.76%. On average, analysts anticipate that Cerus will post ($0.65) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Cerus’ (CERS) “Buy” Rating Reiterated at BTIG Research” was reported by sleekmoney and is owned by of sleekmoney. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://sleekmoney.com/cerus-cers-buy-rating-reiterated-at-btig-research/1859424.html.
In other Cerus news, insider William Mariner Greenman sold 8,786 shares of Cerus stock in a transaction dated Wednesday, March 15th. The shares were sold at an average price of $4.21, for a total value of $36,989.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 14,695 shares of company stock valued at $61,652 in the last quarter. Corporate insiders own 6.60% of the company’s stock.
A number of hedge funds have recently modified their holdings of CERS. Lesa Sroufe & Co boosted its stake in shares of Cerus by 0.3% in the third quarter. Lesa Sroufe & Co now owns 610,792 shares of the biotechnology company’s stock valued at $3,793,000 after buying an additional 1,610 shares during the period. Nuveen Fund Advisors LLC boosted its stake in shares of Cerus by 5.5% in the third quarter. Nuveen Fund Advisors LLC now owns 21,788 shares of the biotechnology company’s stock valued at $135,000 after buying an additional 1,138 shares during the period. State Street Corp boosted its stake in shares of Cerus by 2.2% in the fourth quarter. State Street Corp now owns 1,787,312 shares of the biotechnology company’s stock valued at $7,773,000 after buying an additional 37,981 shares during the period. Salzhauer Michael boosted its stake in shares of Cerus by 1.9% in the third quarter. Salzhauer Michael now owns 292,156 shares of the biotechnology company’s stock valued at $1,814,000 after buying an additional 5,386 shares during the period. Finally, Norges Bank acquired a new stake in shares of Cerus during the fourth quarter valued at $3,407,000. Institutional investors and hedge funds own 68.91% of the company’s stock.
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/cerus-cers-buy-rating-reiterated-at-btig-research/1859424.html
Receive News & Ratings for Cerus Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Co. and related companies with MarketBeat.com's FREE daily email newsletter.